Emerson today announced the formation of an executive committee comprised of leaders in key life sciences sectors to define, review and demonstrate prototypes of Emerson technologies to safely accelerate time to market for life-saving medicines.

Through Emerson’s One-Click Technology Transfer ™ board, Emerson customers FUJIFILM Diosynth Biotechnology, Merck and Pfizer will lead the development of strategies, solutions and guidelines to create a digital production platform for today’s life sciences manufacturing formulation transfer processes. The digital transfer of formulation technology will reduce the time, effort, and risk of managing, sharing, and translating information, enabling patients to access new drug therapies faster.

Emerson’s One-click Technology Transfer ™ program is designed to dramatically reduce the amount of time and money life science organizations spend transferring information – recipes, process steps, parameters, equipment characteristics, quality requirements, and more – between their various critical software solutions.

Emerson will also open a dedicated research center to accelerate the development of one-click technology transfer software. Emerson’s new research center, located at the Singapore Life Sciences Manufacturing Hub, brings together eight of the world’s 10 pharmaceutical companies to design, develop and validate software and digital production platforms.

Nathan Pettus, president of Emerson’s Process Systems and Solutions business, said:

“We have learned from COVID-19 that with highly focused investment and coordination, new treatments can be brought to market safely and quickly. Bringing together industry leaders and setting up a dedicated new research center to drive technology and standards development will help systematize the experience, accelerate the research and development process, and provide patients with life-saving and quality-of-life treatments. The life sciences industry is heavily regulated to ensure reliable and consistent quality of life-saving and improving medicines. “Emerson is proud to work with so many industry leaders to drive this innovation process, driving standards, accelerating the adoption of new technologies and delivering results.”

Life sciences companies currently spend a significant amount of time and money transferring information between different applications and databases, including enterprise resource planning, process and knowledge management, maintenance management, quality management, and automation systems, including formulations, process sequences, operating parameters, equipment characteristics, quality requirements, and more.

Emerson’s one-click technology transfer program digitizes drug formulation and management from invention and development to scale production, provides valuable transitions between drug formulation requirements and manufacturing processes, and results in best practices that unify disparate systems into a single platform. The committee will define reference data models and objects for one-click manufacturing, create a framework for a scalable centralized formula transfer and translation platform, and define and implement versioning and quality control standards, while ensuring that the overall system is easy to use and intuitive.

Data scientists and software developers at Emerson’s Life Sciences Software Development Center in Singapore will use new computer software development techniques to rapidly develop prototypes and test and validate concepts. Software platforms developed through rapid prototyping need to be tested and validated before being appropriately applied to the supply chain of one-click Technology Transfer Council member companies.

The new committee builds on Emerson’s globally recognized position in the life sciences and combines flexible, integrated solutions in the industry. With the acquisition of the Fluxa PKM™ solution and Aspen Software, including AspenTech DataWorks industrial information management software, Emerson is well positioned to develop technologies and standards for fully integrated end-to-end solutions for drug discovery programs.

Lars Petersen, President and CEO of FUJIFILM Diosynth Biotech, said:

“The life sciences industry is a tight-knit community and ecosystem where successful solutions can spread quickly and revolutionize the status quo. The expertise of the One-Click Technology Transfer Executive Committee’s existing partners in the life sciences will help digital solutions scale, standardize and become best practices as it influences life science innovation for the benefit of patients for decades to come.”

Mike Tomasco, vice president of Digital Manufacturing at Pfizer, said:

“Our goal is to move from a document process to a data process to accelerate new product to market and technology transfer. The commercial production of life sciences requires significant capital investment in facilities. One-click technology transfer will help organizations determine the suitability of facilities to help teams move faster, more confidently and cost-effectively from research and development and clinical trials to full production.”